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Objectives: To determine whether patients can understand and use the vaginal pH device in the diagnosis of
vaginitis. To compare whether vaginal pH readings determined by patients and healthcare providers are similar.
TodeterminewhethervaginalpHcanreduceinappropriateover-the-counter(OTC)antifungalmedicationuseand
improve the correct diagnosis of vaginitis.
Methods: One hundred and fifty-one women indicated their belief about the cause of their vaginal infection, read
the instructions of the vaginal pH device package insert, used the device and interpreted the findings. The patient
interpretations were compared with results obtained by healthcare providers, blinded to patient findings.
Results: Over 96% of patients stated that they could easily read the instructions, use the vaginal pH device and
interpret the readings. They obtained the same readings as healthcare professionals (Kappa = 0.9). Restricting
the use of OTC antifungal medications to those individuals with vaginitis symptoms and vaginal pH ≤ 4.5
significantly reduced inappropriate use by approximately 50%, Fisher’s exact test, p-value = 0.018. Conversely,
seeking healthcare provider assessment with vaginal pH > 4.5, leads to correct diagnosis of vaginitis.
Conclusions: ThevaginalpHdevicecanbeusedasanOTCdiagnostictoolbyconsumerswhenavaginalinfection
is suspected. Vaginal pH readings would direct patients whether to purchase an antifungal medication or seek
professional diagnosis from a healthcare provider. Understanding and use of this vaginal pH device could reduce
inappropriate use of OTC antifungal medications by approximately 50% and improve the correct diagnosis of
vaginitis.
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tration (FDA) allowance of over-the-counter
(OTC) vaginal antifungal medication in 19901,
therehavebeennumerousreportsofinappropriate
use of such therapy2–4. These observations are not
surprising because of the high likelihood of
bacterial infections responsible for vaginitis.
Bacterial infections account for 11–64% of vaginal
infections in symptomatic non-pregnant patients5
while trichomonal infections account for 5–25%
of family planning or gynecology clinic visits
and up to 32% in STD clinics6. Physician or
healthcare provider use of vaginal pH testing has
beenshowntobeofutilityindiagnosingthecauses
of vaginitis7–9. We have shown that subjects can
read the package insert and understand the role of
a vaginal pH device10. It is our suggestion that
patients can use the vaginal pH self-test device
(Figure 1) as a screening tool, leading to less
inappropriate use of antifungal medications and
more appropriate use of healthcare provider
examinations.
In order to understand better the place of
vaginal pH testing some historical facts are
reviewed. pH paper has been described to test
vaginal pH in an American medical textbook
published as early as 195011. The early textbook
specifically recommended Nitrazine (phenaph-
thazine)pHpaperforvaginalpHtesting.Thesame
Nitrazine pH paper is used for the vaginal pH
self-test device.
Prior to the availability of the vaginal pH
device12, it was the practice of physicians to press
a strip of pH paper against the vaginal wall
while holding it with either the fingers or a
hemostat or to place it in the secretions from
the vaginal pool collected in the posterior fornix6.
The latter practice is not recommended because
of contamination with cervical mucus, blood or
semenwhichmayresultinanincorrectvaginalpH
reading6 (generally greater than 6.0). The vaginal
pH device makes it convenient for the physician
or patient to obtain a vaginal pH reading from
the lateral outer third of the vagina by mounting
the paper on the end of a probe, allowing for a less
cumbersome procedure and a correct reading.
Secretions from the normal vaginal wall (outer
third) of a reproductive-age female are acidic, in
the pH range of 3.8–4.513. Vaginal homeostasis
is maintained by interrelationships among the
endogenous microflora, metabolic products of
the microflora and estrogen levels13,14. Studies
clearly indicate that estrogen is responsible for
proliferating surface vaginal epithelium15,16.I n
response to estrogen, the glycogen content within
the vaginal cells is increased and released into the
vaginal lumen17, supporting the growth of
various strains of H2O2- and lactic acid-producing
lactobacillae, that are critical for producing an
acidic pH and maintaining vaginal health14.T h e
resulting healthy vaginal microflora is made up
of numerous microorganisms including gram-
positiveandgram-negativeaerobic,facultativeand
obligate anaerobic bacteria14,18.
An elevated vaginal pH level (greater than 4.5,
considered a positive finding) may indicate various
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Figure 1 The OTC version of the pH self-test device is identical to the professional/prescription version, except
for the package insert, which has been modified specifically to address the needs of the lay user. Both versions are
comprised of a plastic probe with pH paper on one end, a color chart and a package insert. The probe and color
chart are illustrated aboveconditions, including bacterial infections such as
bacterial vaginosis (BV), Trichomonas vaginalis
infections, group B streptocococcus (GBS) or
other pathogenic organisms9. However, like an
elevated temperature, an elevated pH alone is
only presumptive and not diagnostic. A diagnosis
of the underlying condition or cause of the
elevated pH should be established by obtaining
additional history, performing tests and observing
the woman’s signs and symptoms.
Although prescribed for vaginal testing decades
before, the seminal work establishing the
importance of vaginal pH in the diagnosis of
vaginal infections was confirmed by Amsel and
co-investigators in the early 1980s. The Amsel
criteria remain the cornerstone for differential
diagnosis of BV today7, with vaginal pH alone
providingthegreatestsensitivityofthefourclinical
signs, but the lowest specificity19. Many clinicians
today determine vaginal pH routinely as part of
well-woman examinations and as part of the
diagnostic process for patients presenting with
symptoms of vaginitis20,21.
This study was conducted to determine
whether patients could understand and use a
vaginal pH device and interpret test results com-
pared with those made by a healthcare provider, as
an aid in the diagnosis of vaginitis. Additionally,
could appropriate use and interpretation of a
vaginal pH device reduce the numbers of
individuals inappropriately using OTC antifungal
medication and lead to correct diagnoses of
vaginitis?
SUBJECTS AND METHODS
The study was conducted under the oversight
of the IRB Company, Camino de los Mares,
CA. Three investigational sites participated in the
study: one private practice in North Dakota, one
private practice in California and one health clinic
in California. These individuals are listed in the
acknowledgement section. The patients selected
for study were of varied background, educational
levels and ages, who were target users (sympto-
maticpatients)andnormalcontrols(asymptomatic
patients). As women presented at the participating
centers, they were screened to see if they met
the inclusion or exclusion criteria. Women who
qualified for the study were asked to participate
and those who agreed signed informed consents.
Theinclusioncriteria,forsymptomaticwomen,
includedvaginalsignsorsymptomssuchasitching,
burning, unpleasant odor, unusual discharge and
that they have regular menstrual periods. The
inclusion criteria for women without symptoms,
stipulated that they have regular menstrual periods
and be visiting the clinic for routine examination
for a non-vaginally related matter. Patients were
excluded if they were not mentally or physically
capable of reading the instructions and/or
performing the test. They were also excluded
if they had douched or used contraceptive
creams or gels within the last 24 hours; had un-
protected sexual intercourse within the last
24 hours; were currently menstruating or the last
menstrual period had not been over for 5 days; or
were currently pregnant.
Each participant was taken to an examination
room and provided a vaginal pH self-test device,
thepackageinsertandapatientquestionnaire.The
patient was then asked to read the package insert,
perform the test and complete the questionnaire
after performing the test in privacy. Completed
questionnaires were immediately given to the
study coordinator who kept the results blinded
from the patient’s healthcare provider (physician
or nurse practitioner).
After the patient had finished, the healthcare
provider performed a vaginal pH test using the
vaginal pH device. A medical examination appro-
priate to the nature of the patient visit, including
microscopy or culture when appropriate, was then
carried out. The healthcare provider recorded the
test result and completed the study questionnaire
without asking the patient any questions regard-
ing her test, its result or her answers to the
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Investigational
site
Condition
Normal Symptomatic Total
1
2
3
Total
11
10
12
33
38
40
40
118
49
50
52
151
Table 1 Distribution of patients by investigational
site and presenting conditionquestions. The healthcare provider was asked to
distinguish between yeast, bacteria or other, in
the same manner as we had asked the patients
who were not expected to know or diagnose
bacterial vaginosis (BV). For practical purposes a
diagnosis of ‘bacteria’ is consistent with BV.
The test results were analyzed using standard
statistical methods, including the Fisher’s exact
test (FET), while the exact permutational version
of the Kappa statistic was performed for the extent
of agreement between the results of the test
when used by patients and healthcare providers
using SAS Version 8.01 PROC FREQ22 and
Proc-StatXact 423 for SAS.
RESULTS
The distribution of patients by site and presenting
condition is provided in Table 1. One hundred
and fifty-one women were enrolled in this
study. Thirty-three of the 151 women (22%) were
normal(asymptomatic)and118(78%)weresymp-
tomatic.Ofthe118symptomaticpatients,96were
premenopausal, not pregnant, and with a uterus
in situ. The healthcare provider did not provide a
final diagnosis in eight, leaving 88 symptomatic
premenopausal patients for whom patient and
healthcare diagnoses were available for analysis.
Because the assessment of the product’s ease of
use or the readability of the instructions for use
are not influenced by exclusion criteria, the
entire population of enrolled patients was used
in selected analyses.
The demographics of the enrolled patients are
provided in Table 2. The women ranged in age
from 17 to 73 years old (average 34.1). The study
included women with a diversity of ethnic back-
grounds. The educational backgrounds of the
women were also diverse ranging from 0 years
of formal education to graduate school.
The concordance (represented by a Kappa
statistic) between the vaginal pH recorded by
the patient and that recorded by the healthcare
provider were evaluated separately for all patients
and premenopausal patients. The findings were
examined considering both the pH readings as
discrete values (4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5):
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Demographic
characteristics
Value/number
of patients
Percentage of
patients
Age, years
Average (n = 149)
Minimum
Maximum
No response given
34.1
17
73
2
Ethnicity
Caucasian
African American
Hispanic
Asian American
Other
No response given
59
5
80
2
1
4
39
3
53
1
1
3
Years of education
0–12 (actual range)
13–16
> 16 (graduate)
No response given
87
44
3
17
58
29
2
11
Table 2 Demographic characteristics of patients
Healthcare providers’ diagnoses
Patients’ initial
self-diagnoses Yeast
Bacteria/
trichomonas Normal
No conclusion
or no response Total Subtotal*
Yeast
Bacteria
Yeast and bacteria
Other
No response given
22
2
1
0
3
13
3
1
1
3
16
1
0
10
12
3
0
0
3
2
54
6
2
14
20
51
6
2
11
18
Total 28 21 39 8 96 88
*The patients for whom the healthcare provider rendered a diagnosis of vaginitis
Table 3 Initial patients’ self-diagnoses versus healthcare providers’ diagnosesKappa for all, 0.891 and for premenopausal, 0.898
and as binary values based around the cut-off of
4.5 (dichomotous: ≤ 4.5 and > 4.5): Kappa for
all, 0.870 and for premenopausal, 0.880. The
findings demonstrate a high degree of concor-
dance (generally considered 0.8 to 1.0) for all four
analyses.
Of the 88 symptomatic premenopausal women
whohadadiagnosisdocumentedbythehealthcare
provider, 32% (28/88) were diagnosed with yeast,
23% (21/88) with bacteria or trichomonas and
45% (39/88) were found to be normal (Table 3).
At the time of their enrollment in the study,
51 of the 88 symptomatic premenopausal women
believedtheyhadayeastinfectionatentryintothe
studybeforeusingthevaginalpHdevice(58%).Of
these 51 women, 43% (22/51) were diagnosed as
having a yeast infection, 26% (13/51) as having
a bacterial or trichomonas infection and 31%
(16/51) were diagnosed as normal by the health-
care provider examination. Therefore, if all 51
women had self-medicated themselves with OTC
antifungal medications, 57% (29/51) would have
been wrong. Of the 29 who would have misused
antifungal medication, 45% (13/29) would
have continued to suffer an opportunistic un-
treated bacterial infection during their course of
self-medication.
After performing the vaginal pH test (Table 4),
when the test was less than or equal to 4.5, 42%
(21/50) thought they had a yeast infection while
76% (16/21) actually had a yeast infection. This
represents a significant reduction in misuse of
antifungal medications of greater than 50%, from
57% (29/51) to 24% (5/21), FET = 0.018. Of
the five patients without a yeast infection, one
(20%) would have continued to suffer from an
opportunistic bacterial infection. Thus, inappro-
priate therapy for opportunistic infections would
have been reduced from 45% (13/29) to 20%
(1/5), FET = 0.38, a non-significant reduction
because of small numbers. When the test was
greater than 4.5, 13% (5/38) had a yeast infec-
tion, as determined by the healthcare provider
examination.
In order to determine vaginal pH test per-
formance, standard definitions were used
(Table 4)24. The information contained in Table 5
was re-formulated into a dichotomous form
(Table 6), which permitted the calculation of test
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Disease positive (+) Disease negative (− ) Total
Test result positive (+)
Test result negative (−)
Total
TP
FN
TP+FN
FP
TN
FP+TN
TP+FP
FN+TN
All
Sensitivity = TP/(TP+FN) Specificity = TN/(FP+TN)
TP, true positive; FP, false positive; FN, false negative; TN, true negative; positive predictive value (PPV) = TP/(TP+FP); false-positive
rate = (100% – PPV); negative predictive value (NPV) = TN/FN+TN); false-negative rate = (100% – NPV)
Table 4 Test performance definitions
24
HCP: pH > 4.5 HCP: pH ≤ 4.5
Yeast B/T Normal Total Yeast B/T Normal Total
Grand
Total
Patient’s decision after self-test of
vaginal pH device:
Rx with OTC anti-fungal medications*
Contact healthcare provider (HCP)**
Do nothing***
3
1
1
2
16
2
4
6
3
9
23
6
16
5
2
1
0
0
4
16
6
21
21
8
30
44
14
Total 5 20 13 38 23 1 26 50 88
B = bacterial, T = trichomonas; FET = Fisher’s exact test (p-value): *3/9 versus 16/21 = 0.04, **17/23 versus 5/21 = 0.002,
***3/6 versus 2/8 = 0.58
Table 5 Patient’s response after performing vaginal pH test and healthcare provider’s (HCP) diagnosisperformanceforvaginalpHinthisstudy(Table7).
Since the true prevalence of BV in any sympto-
matic, non-pregnant population is not known
(rangingsomewherebetween11and64%)5,corre-
sponding to a vaginal pH > 4.5, the positive
predictive value (PPV) and negative predictive
value (NPV) were also calculated for three addi-
tional assumptions for prevalence (0.20, 0.30 and
0.50). These assumptions lie within the range of
the reported medical literature5. The last column
of Table 7 lists the test characteristics of the com-
posite of three studies taken from the literature
where healthcare providers obtained vaginal pH
and diagnosed the cause of the vaginitis7–9.
The patient was given a questionnaire to
complete after reading the package insert and
performing the test. To the question, ‘Was the
test easy to use?’ 146 patients said ‘yes’, two said
‘no’ and three did not respond. Assuming a
worst-case approach in which the ‘absence of
a response’ is considered a ‘no’, 97% (146/151)
of the women found the test easy to use. To the
question, ‘Were the instructions easy to follow?’
145 patients said ‘yes’, three said ‘no’ and three
did not respond. Again assuming a worst-case
approach, 96% (146/151) of the women found
the instructions easy to follow.
DISCUSSION
This study demonstrates that the device and
labeling are well designed and meet the needs for
home testing. Nearly all of the patients found
the test easy to use and the instructions easy to
follow. A parallel study demonstrated that age,
years of education, ethnicity and clinic location
did not alter the ability of subjects to read and
understand the package insert of the vaginal pH
device10. Furthermore, the high degree of con-
cordance (0.870 to 0.891) of patients’ vaginal pH
readings with those obtained by the healthcare
provider suggests that the vaginal pH device is
designed and labeled appropriately.
This study suggests that by restricting antifungal
use to symptomatic patients having vaginal
pH ≤ 4.5, would reduce misuse of antifungals by
about 50%. Such misuse and overuse of incorrect
treatment by symptomatic women is extensively
reported in the medical literature2–4. According
to a survey of 390 gynecologists conducted by
the Institute of Epidemiological Research, an
estimated 44% of patients diagnosed with bac-
terial vaginosis (BV) had initially treated them-
selves with OTC antifungal medications for
what they had improperly assumed was a yeast
Improving appropriate use of antifungal medications Roy et al.
214 • INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY
Healthcare providers’ diagnoses
Bacteria (B)/trichomonas (T) Yeast or normal Grand total
Patients’ pH readings
pH > 4.5
pH < 4.5
Total
20
1
21
18
49
67
38
50
88
Table 6 Patient pH readings versus healthcare providers’ diagnoses (dichotomous arrangement)
Observed results
from this study
(Table 6) Assuming a true prevalence of the following
Composit
values from
references 7–9
Sensitivity
Specificity
Prevalence
Positive predictive value
Negative predictive value
0.95
0.73
0.24
0.53
0.98
0.2
0.47
0.98
0.3
0.6
0.97
0.5
0.78
0.94
0.95
0.61
0.3
0.51
0.97
Table 7 Study test performance as a function of various prevalence assumptions and compared with literature
estimatesinfection20. This observation is amplified by a
studyofpatientself-diagnosisin111womenacross
the US, in which 67% of women who believed
they had a yeast infection were found to be
incorrect25. Because of the improper use of
OTC antifungal medications, the vaginal micro-
flora may be altered26 and opportunistic infections
such as BV may go unchecked and untreated.
Vaginitis, in particular BV, has been associated
with increased risk of serious obstetric and
gynecologic complications and disorders27–31.
Since the patient is advised to see her doctor/
healthcare provider when the test is positive
(pH > 4.5), a false-positive test would only cause
the symptomatic patient to visit her healthcare
provider for proper diagnosis of an abnormal con-
dition. The probability of a false-negative vaginal
pHinasymptomaticpatientisrelativelylowgiven
the specificities reported in the medical literature
(and summarized in this document) and supported
by the clinical findings reported above. Further,
the symptomatic patient who has a negative
(pH ≤ 4.5) finding would be in the same position
she is today (i.e. she could choose to initiate treat-
ment with an OTC antifungal medication or see
her doctor). Since there is no OTC treatment
currently available for bacterial and trichomonas
infection,thepotentialgainofreducingthemisuse
of antifungal medications in the larger number of
true-positive and true-negative cases clearly out-
weighs the risk of a false-negative finding.
It is noteworthy that the test characteristics
of the patient self-test of the vaginal pH device
were almost exactly the same as those of
the composite of three studies taken from the
literature7–9 where healthcare providers obtained
vaginalpHanddiagnosedthecauseofthevaginitis
(Table 7). Thus, the test performance characteris-
tics of the vaginal pH self-test device are reason-
able and acceptable as an aid in the diagnosis of
vaginitis. The correct use of such a device could
lead to a more appropriate use of OTC anti-fungal
medications and will encourage a more appropri-
ate utilization of healthcare providers. This leads
to a proper diagnoses of vaginitis and improved
health for women*.
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